Olanzapine and sibutramine have opposing effects on the motivation for palatable food

Behavioural Pharmacology

Volumn 23, Issue 2, 2012, Pages 198-204

  Van Der Zwaal, Esther M ^a   Janhunen, Sanna K ^a   Luijendijk, Mieneke C M ^a   Baclesanu, Roxana ^a   Vanderschuren, Louk J M J ^a,b   Adan, Roger A H ^a   La Fleur, Susanne E ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

food motivated behavior; noradrenaline; olanzapine; palatable food; progressive ratio of reinforcement; serotonin; sibutramine; sucrose

Indexed keywords

OLANZAPINE; SIBUTRAMINE; SUCROSE;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; LOW DRUG DOSE; MALE; MOTIVATION; NONHUMAN; PALATABILITY; PERFORMANCE; RAT; REINFORCEMENT; SUGAR INTAKE;

ANIMALS; ANTIPSYCHOTIC AGENTS; APPETITE DEPRESSANTS; BENZODIAZEPINES; CONDITIONING, OPERANT; CYCLOBUTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EATING; MALE; MOTIVATION; RATS; RATS, WISTAR; REINFORCEMENT SCHEDULE;

EID: 84858699286     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283512ca1     Document Type: Article

References (53)

1. Ahnaou A, Megens AA, Drinkenburg WH (2003). The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats. Neuropsychobiology 48:47-54. (Pubitemid 36928715)
2. Barbano MF, Le Saux M, Cador M (2009). Involvement of dopamine and opioids in the motivation to eat: influence of palatability, homeostatic state, and behavioral paradigms. Psychopharmacology (Berl) 203:475-487.
3. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD (2001). Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62:231-238. (Pubitemid 32428761)
4. Berridge KC, Kringelbach ML (2008). Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology (Berl) 199:457-480.
5. Blaustein JD, Wade GN (1976). Ovarian influences on the meal patterns of female rats. Physiol Behav 17:201-208.
6. Blouin M, Tremblay A, Jalbert ME, Venables H, Bouchard RH, Roy MA, Almeras N (2008). Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring) 16:1780-1787.
7. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM (2010). Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31:484-497.
8. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, et al. (1998). Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 3:76-80. (Pubitemid 28045189)
9. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96. (Pubitemid 26053226)
10. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, et al. (1999). Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37:107-122. (Pubitemid 29167031)
11. Chapelot D, Marmonier C, Thomas F, Hanotin C (2000). Modalities of the food intake-reducing effect of sibutramine in humans. Physiol Behav 68: 299-308. (Pubitemid 30100696)
12. Cifani C, Polidori C, Melotto S, Ciccocioppo R, Massi M (2009). A preclinical model of binge eating elicited by yo-yo dieting and stressful exposure to food: effect of sibutramine, fluoxetine, topiramate, and midazolam. Psychopharmacology (Berl) 204:113-125.
13. Cilia J, Piper DC, Upton N, Hagan JJ (2001). Clozapine enhances breakpoint in common marmosets responding on a progressive ratio schedule. Psychopharmacology (Berl) 155:135-143. (Pubitemid 32417821)
14. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005). A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181:80-89. (Pubitemid 41440918)
15. Cooper GD, Pickavance LC, Wilding JP, Harrold JA, Halford JC, Goudie AJ (2007). Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 21:405-413. (Pubitemid 47077303)
16. Costa Silva JA, Alvarez N, Mazzotti G, Gattaz WF, Ospina J, Larach V, et al. 2001. Olanzapine as alternative therapy for patients with haloperidolinduced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol 21: 375-381. (Pubitemid 32673026)
17. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, et al. (2001). Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 158:1719-1722. (Pubitemid 32923669)
18. Evenden J, Ko T (2007). The effects of anorexic drugs on free-fed rats responding under a second-order FI15-min (FR10:S) schedule for high incentive foods. Behav Pharmacol 18:61-69. (Pubitemid 46103284)
19. Galistu A, Modde C, Pireddu MC, Franconi F, Serra G, D'Aquila PS (2011). Clozapine increases reward evaluation but not overall ingestive behaviour in rats licking for sucrose. Psychopharmacology (Berl) 216:411-420.
20. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, et al. (2002). Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159:1055-1057. (Pubitemid 34586957)
21. Grignaschi G, Fanelli E, Scagnol I, Samanin R (1999). Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats. Br J Pharmacol 127:1190-1194. (Pubitemid 29326642)
22. Halford JC, Boyland EJ, Cooper SJ, Dovey TM, Huda MS, Dourish CT, et al. (2010). The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. J Psychopharmacol 24:99-109.
23. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, et al. (2005). A double-blind, placebo-controlled trial of sibutramine for olanzapineassociated weight gain. Am J Psychiatry 162:954-962. (Pubitemid 40676209)
24. Henderson DC, Borba CP, Daley TB, Boxill R, Nguyen DD, Culhane MA, et al. (2006). Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry 18:99-105. (Pubitemid 43879897)
25. Higgs S, Cooper AJ, Barnes NM (2011). Reversal of sibutramine-induced anorexia with a selective 5-HT(2C) receptor antagonist. Psychopharmacology (Berl) 214:941-947.
26. Hodos W (1961). Progressive ratio as a measure of reward strength. Science 134:943-944.
27. Jackson HC, Needham AM, Hutchins LJ, Mazurkiewicz SE, Heal DJ (1997). Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 121:1758-1762. (Pubitemid 27343407)
28. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M (2002). Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 76:365-377. (Pubitemid 34765590)
29. Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, Wehmeier PM, et al. (2007). Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol 27:662-666. (Pubitemid 351339453)
30. La Fleur SE, Vanderschuren LJ, Luijendijk MC, Kloeze BM, Tiesjema B, Adan RA (2007). A reciprocal interaction between food-motivated behavior and dietinduced obesity. Int J Obes (Lond) 31:1286-1294. (Pubitemid 47172615)
31. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009a). Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41.
32. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. (2009b). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152-163.
33. Luque CA, Rey JA (2002). The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 440:119-128. (Pubitemid 34458019)
34. Malone M (2005). Medications associated with weight gain. Ann Pharmacother 39:2046-2055. (Pubitemid 41745950)
35. McElroy SL, Frye MA, Altshuler LL, Suppes T, Hellemann G, Black D, et al. (2007). A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord 9:426-434. (Pubitemid 46865373)
36. Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, Siu C (2009). Weight effects associated with antipsychotics: A comprehensive database analysis. Schizophr Res 110:103-110.
37. Pratt WE, Connolly ME (2010). Contrasting effects of systemic and central sibutramine administration on the intake of a palatable diet in the rat. Neurosci Lett 481:30-34.
38. Richardson NR, Roberts DC (1996). Progressive ratio schedules in drug selfadministration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66:1-11. (Pubitemid 26180064)
39. Roberts DC, Bennett SA (1993). Heroin self-administration in rats under a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 111:215-218. (Pubitemid 23135082)
40. Rowland NE, Marshall M, Roth JD (2000). Comparison of either norepinephrineuptake inhibitors or phentermine combined with serotonergic agents on food intake in rats. Psychopharmacology (Berl) 149:77-83. (Pubitemid 30187370)
41. Salamone JD, Correa M (2002). Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 137:3-25. (Pubitemid 35346426)
42. Sanders AC, Hussain AJ, Hen R, Zhuang X (2007). Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward. Neuropsychopharmacology 32:2321-2329. (Pubitemid 47587680)
43. Scherk H, Pajonk FG, Leucht S (2007). Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 64: 442-455. (Pubitemid 46556468)
44. Smith LA, Cornelius V, Warnock A, Bell A, Young AH (2007). Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 9:394-412. (Pubitemid 46876306)
45. Solinas M, Goldberg SR (2005). Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology 30:2035-2045. (Pubitemid 43093503)
46. Stauffer VL, Lipkovich I, Hoffmann VP, Heinloth AN, McGregor HS, Kinon BJ (2009). Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents;a post-hoc analysis. BMC Psychiatry 9:12.
47. Tallett AJ, Blundell JE, Rodgers RJ (2009). Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats. Behav Brain Res 198:359-365.
48. Ter Haar MB (1972). Circadian and estrual rhythms in food intake in the rat. Horm Behav 3:213-219.
49. Thomas GH, Babbs AJ, Chatfield RE, Krulle TM, Widdowson PS, Provost D, McCormack JG (2009). 5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats. Obesity (Silver Spring) 17:467-473.
50. van der Zwaal EM, Luijendijk MC, Evers SS, la Fleur SE, Adan RA (2010). Olanzapine affects locomotor activity and meal size in male rats. Pharmacol Biochem Behav 97:130-137.
51. Ward SJ, Lefever TW, Jackson C, Tallarida RJ, Walker EA (2008). Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice. J Pharmacol Exp Ther 325:567-576. (Pubitemid 351574781)
52. Zhang Z, Rickard JF, Asgari K, Body S, Bradshaw CM, Szabadi E (2005a). Quantitative analysis of the effects of some 'atypical' and 'conventional' antipsychotics on progressive ratio schedule performance. Psychopharmacology (Berl) 179:489-497. (Pubitemid 40575668)
53. Zhang Z, Rickard JF, Body S, Asgari K, Bradshaw CM, Szabadi E (2005b). Comparison of the effects of clozapine and 8-hydroxy-2-(di-n-propylamino)- tetralin (8-OH-DPAT) on progressive ratio schedule performance: evidence against the involvement of 5-HT1A receptors in the behavioural effects of clozapine. Psychopharmacology (Berl) 181:381-391. (Pubitemid 41508811)